321 related articles for article (PubMed ID: 25801699)
21. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
22. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
25. Presentation and management of gastrointestinal stromal tumours.
Mongan AM; Malik V; Rowley S; Claxton Z; Muldoon C; O'Toole D; Ravi N; Reynolds JV
Ir Med J; 2013 Jun; 106(6):176-9. PubMed ID: 23909154
[TBL] [Abstract][Full Text] [Related]
26. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
[TBL] [Abstract][Full Text] [Related]
27. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
Rutkowski P; Andrzejuk J; Bylina E; Osuch C; Switaj T; Jerzak vel Dobosz A; Grzesiakowska U; Jurkowska M; Woźniak A; Limon J; Dębiec-Rychter M; Siedlecki JA
Med Oncol; 2013 Dec; 30(4):765. PubMed ID: 24217870
[TBL] [Abstract][Full Text] [Related]
28. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
29. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
Chacón M; Eleta M; Espindola AR; Roca E; Méndez G; Rojo S; Pupareli C
Future Oncol; 2015; 11(6):953-64. PubMed ID: 25760976
[TBL] [Abstract][Full Text] [Related]
30. Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10 cm: A Single-Institution Experience in China.
Shen C; Chen H; Yin Y; Chen J; Tang S; Zhang B; Han L; Chen Z; Chen J
Medicine (Baltimore); 2015 Jul; 94(28):e1117. PubMed ID: 26181546
[TBL] [Abstract][Full Text] [Related]
31. Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
Tirumani SH; Jagannathan JP; Krajewski KM; Shinagare AB; Jacene H; Ramaiya NH
AJR Am J Roentgenol; 2013 Oct; 201(4):801-10. PubMed ID: 24059369
[TBL] [Abstract][Full Text] [Related]
32. Managing GIST in the imatinib era: optimization of adjuvant therapy.
Trent JC; Subramanian MP
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
[TBL] [Abstract][Full Text] [Related]
33. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
Chang SC; Liao CH; Wang SY; Tsai CY; Chiang KC; Cheng CT; Yeh TS; Chen YY; Ma MC; Liu CT; Yeh CN
Medicine (Baltimore); 2015 Jun; 94(24):e1014. PubMed ID: 26091448
[TBL] [Abstract][Full Text] [Related]
35. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
Call J; Walentas CD; Eickhoff JC; Scherzer N
BMC Cancer; 2012 Mar; 12():90. PubMed ID: 22429770
[TBL] [Abstract][Full Text] [Related]
36. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.
Wilkinson MJ; Fitzgerald JE; Strauss DC; Hayes AJ; Thomas JM; Messiou C; Fisher C; Benson C; Tekkis PP; Judson I
Br J Surg; 2015 Jul; 102(8):965-71. PubMed ID: 25970743
[TBL] [Abstract][Full Text] [Related]
37. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
[TBL] [Abstract][Full Text] [Related]
38. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
Cananzi FC; Belgaumkar A; Lorenzi B; Mudan S
ANZ J Surg; 2014 Dec; 84(12):937-42. PubMed ID: 25444423
[TBL] [Abstract][Full Text] [Related]
39. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
[No Abstract] [Full Text] [Related]
40. [Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor].
Zhang XH; Wu H; He YL; Ma JP; Chen CQ; Xu JB; Cai SR; Han FH; Zhan WH
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):243-6. PubMed ID: 22454169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]